{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:04:37Z","timestamp":1780074277821,"version":"3.54.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40119-026-00451-x","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:14:44Z","timestamp":1779441284000},"page":"135-153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Summary of Cardiometabolic Disorders in the Maghreb: Insights from the 2025 Saclay Cardiometabolic Summit"],"prefix":"10.1007","volume":"15","author":[{"given":"Faouzi","family":"Addad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Amara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Bennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Boccara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Abed","family":"Bouraghda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Chettibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinde","family":"Iraqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma Siham","family":"El Khayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e8s","family":"Khochtali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Laredj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"Skhiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Soufiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4889-2920","authenticated-orcid":false,"given":"Marilucy","family":"Lopez-Sublet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"3","key":"451_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamaoncol.2021.6987","volume":"8","author":"JM Kocarnik","year":"2022","unstructured":"Kocarnik JM, Compton K, Dean FE, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease study 2019. JAMA Oncol. 2022;8(3):420\u201344. https:\/\/doi.org\/10.1001\/jamaoncol.2021.6987.","journal-title":"JAMA Oncol"},{"issue":"25","key":"451_CR2","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982\u20133021. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.010.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"451_CR3","doi-asserted-by":"publisher","DOI":"10.5334\/gh.1288","volume":"19","author":"M Di Cesare","year":"2024","unstructured":"Di Cesare M, Perel P, Taylor S, et al. The heart of the world. Glob Heart. 2024;19(1):11. https:\/\/doi.org\/10.5334\/gh.1288.","journal-title":"Glob Heart"},{"key":"451_CR4","unstructured":"Algerie Presse Service. Cardiovascular diseases are the leading cause of death in Algeria [in French]. 2021. https:\/\/www.aps.dz\/sante-science-technologie\/119636-les-maladies-cardiovasculaires-premiere-cause-de-mortalite-en-algerie. Accessed 24 July 2025."},{"key":"451_CR5","unstructured":"LaPresse. Morocco: 38% of deaths are caused by cardiovascular diseases [in French]. 2022. https:\/\/ma.lapresse.it\/sante-ma\/2022\/10\/01\/maroc-38-des-deces-sont-causes-par-les-maladies-cardiovasculaires\/. Accessed 13 Nov 2025."},{"key":"451_CR6","unstructured":"Jomni M. Tunisia: Cardiovascular diseases are the leading cause of death recorded each year [in French]. 2022. https:\/\/www.aa.com.tr\/fr\/sante\/tunisie-les-maladies-cardiovasculaires-principale-cause-de-d%C3%A9c%C3%A8s-enregistr%C3%A9e-chaque-ann%C3%A9e-\/2699040#. Accessed 13 Nov 2025."},{"issue":"9","key":"451_CR7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45542","volume":"15","author":"AR Khan","year":"2023","unstructured":"Khan AR, Salama AH, Aleem Z, Alfakeer H, Alnemr L, Shareef AMM. The promising frontier of cardiometabolic syndrome: a new paradigm in cardiology. Cureus. 2023;15(9):e45542. https:\/\/doi.org\/10.7759\/cureus.45542.","journal-title":"Cureus"},{"key":"451_CR8","unstructured":"World Health Organization. Cardiovascular diseases (CVDs). 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds). Accessed 13 Nov 2022."},{"issue":"9","key":"451_CR9","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.cjca.2015.06.035","volume":"31","author":"K Yeates","year":"2015","unstructured":"Yeates K, Lohfeld L, Sleeth J, Morales F, Rajkotia Y, Ogedegbe O. A global perspective on cardiovascular disease in vulnerable populations. Can J Cardiol. 2015;31(9):1081\u201393. https:\/\/doi.org\/10.1016\/j.cjca.2015.06.035.","journal-title":"Can J Cardiol"},{"key":"451_CR10","unstructured":"International Diabetes Federation. IDF diabetes atlas. 2025. https:\/\/diabetesatlas.org\/resources\/idf-diabetes-atlas-2025\/#. Accessed 11 Nov 2025."},{"issue":"5","key":"451_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41371-021-00554-z","volume":"36","author":"M Abboud","year":"2022","unstructured":"Abboud M, Karam S. Hypertension in the Middle East: current state, human factors, and barriers to control. J Hum Hypertens. 2022;36(5):428\u201336. https:\/\/doi.org\/10.1038\/s41371-021-00554-z.","journal-title":"J Hum Hypertens"},{"issue":"6","key":"451_CR12","first-page":"1303","volume":"21","author":"SA Meo","year":"2017","unstructured":"Meo SA, Usmani AM, Qalbani E. Prevalence of type\u00a02 diabetes in the Arab world: impact of GDP and energy consumption. Eur Rev Med Pharmacol Sci. 2017;21(6):1303\u201312.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"451_CR13","unstructured":"International Diabetes Federation. IDF global clinical practice recommendations for managing type\u00a02 diabetes. 2025. https:\/\/idf.org\/media\/uploads\/2025\/04\/IDF_Rec_2025.pdf. Accessed 11 Nov 2025."},{"issue":"10304","key":"451_CR14","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2021","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104\u00a0million participants. Lancet. 2021;398(10304):957\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(21)01330-1.","journal-title":"Lancet"},{"issue":"3","key":"451_CR15","first-page":"345","volume":"9","author":"AA Al-Rasheedi","year":"2015","unstructured":"Al-Rasheedi AA. Glycemic control among patients with type\u00a02 diabetes mellitus in countries of Arabic Gulf. Int J Health Sci (Qassim). 2015;9(3):345\u201350.","journal-title":"Int J Health Sci (Qassim)"},{"issue":"9","key":"451_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.124.037555","volume":"14","author":"LN Aminde","year":"2025","unstructured":"Aminde LN, Agbor VN, Fongwen NT, et al. High burden and trend in nonadherence to blood pressure-lowering medications: meta-analysis of data from over 34\u2009000 adults with hypertension in sub-Saharan Africa. J Am Heart Assoc. 2025;14(9):e037555. https:\/\/doi.org\/10.1161\/jaha.124.037555.","journal-title":"J Am Heart Assoc"},{"key":"451_CR17","unstructured":"World Bank. Low & middle income. 2025. https:\/\/data.worldbank.org\/country\/low-and-middle-income. Accessed 13 Nov 2025."},{"key":"451_CR18","unstructured":"World Health Organization. Algeria STEPS Survey 2016\u20132017: fact sheet. 2017. https:\/\/www.who.int\/publications\/m\/item\/2016-2017-steps-fact-sheet-algeria. Accessed 12 Mar 2026."},{"key":"451_CR19","unstructured":"Minist\u00e8re de la sant\u00e9 du Maroc. Report of the national survey on common risk factors for non-communicable diseases, STEPS, 2017\u20132018 [in French]. 2018. https:\/\/cdn.who.int\/media\/docs\/default-source\/ncds\/ncd-surveillance\/data-reporting\/morocco\/steps\/steps-report-2017-2018-morocco-final.pdf?sfvrsn=d064ef54_3. Accessed 13 Nov 2025."},{"issue":"1","key":"451_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.acvdsp.2022.10.253","volume":"15","author":"R Jemaa","year":"2023","unstructured":"Jemaa R, Razgallah R, Rais L, Ghorbel IB, Feki M, Kallel A. Prevalence of diabetes in the Tunisian population: results of the ATERA-survey. Arch Cardiovasc Dis Suppl. 2023;15(1):131. https:\/\/doi.org\/10.1016\/j.acvdsp.2022.10.253.","journal-title":"Arch Cardiovasc Dis Suppl"},{"issue":"9","key":"451_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare9091229","volume":"9","author":"A Bounihi","year":"2021","unstructured":"Bounihi A, Saidi H, Bouazza A, Benbaibeche H, Azzouz M, Koceir EA. Dietary diversity as a risk factor for obesity in Algerian patients with type\u00a02 diabetes mellitus. Healthcare Basel. 2021;9(9):1229. https:\/\/doi.org\/10.3390\/healthcare9091229.","journal-title":"Healthcare Basel"},{"issue":"3","key":"451_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/2042018816643227","volume":"7","author":"A Chadli","year":"2016","unstructured":"Chadli A, El Aziz S, El Ansari N, et al. Management of diabetes in Morocco: results of the International Diabetes Management Practices Study (IDMPS) \u2013 wave 5. Ther Adv Endocrinol Metab. 2016;7(3):101\u20139. https:\/\/doi.org\/10.1177\/2042018816643227.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"451_CR23","unstructured":"Abid M, Aissa EB. Management of diabetes in Tunisia: results from a cross-sectional study of the International Diabetes Management Practices Study (IDMPS) \u2013 wave 7. 2023. https:\/\/auctoresonline.org\/article\/management-of-diabetes-in-tunisia-results-from-a-cross-sectional-study-of-the-international-diabetes-management-practices-study-idmps--wave-7. Accessed 09 Jan 2026."},{"issue":"9","key":"451_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-021-01159-0","volume":"23","author":"N Mohammadian Khonsari","year":"2021","unstructured":"Mohammadian Khonsari N, Shahrestanaki E, Ejtahed HS, et al. Long-term trends in hypertension prevalence, awareness, treatment, and control rate in the Middle East and North Africa: a systematic review and meta-analysis of 178 population-based studies. Curr Hypertens Rep. 2021;23(9):41. https:\/\/doi.org\/10.1007\/s11906-021-01159-0.","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"451_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/HJH.0b013e32835a6611","volume":"31","author":"C Nejjari","year":"2013","unstructured":"Nejjari C, Arharbi M, Chentir MT, et al. Epidemiological Trial of Hypertension in North Africa (ETHNA): an international multicentre study in Algeria, Morocco and Tunisia. J Hypertens. 2013;31(1):49\u201362. https:\/\/doi.org\/10.1097\/HJH.0b013e32835a6611.","journal-title":"J Hypertens"},{"key":"451_CR26","unstructured":"World Health Organization. Global report on hypertension: the race against a silent killer. 2023. https:\/\/www.who.int\/publications\/i\/item\/9789240081062. Accessed 13 Nov 2025."},{"issue":"9","key":"451_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.31080\/ASMS.2024.08.1875","volume":"8","author":"A Kallel","year":"2024","unstructured":"Kallel A, Ghorbel IB, Rais L, Razgallah R, Feki M, Jemaa R. The ATREA survey: study design and main results. Acta Sci Med Sci. 2024;8(9):155\u201360. https:\/\/doi.org\/10.31080\/ASMS.2024.08.1875.","journal-title":"Acta Sci Med Sci"},{"issue":"1_Suppl","key":"451_CR28","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1016\/j.acvd.2024.10.219","volume":"118","author":"R Jemaa","year":"2025","unstructured":"Jemaa R, Razgallah R, Lamia R, Ben Ghorbel I, Kallel A. Prevalence of pre-hypertension and hypertension and associated risk factors among Tunisian population: results of the ATERA-survey [JESFC abstract: 087]. Arch Cardiovasc Dis. 2025;118(1_Suppl):S116. https:\/\/doi.org\/10.1016\/j.acvd.2024.10.219.","journal-title":"Arch Cardiovasc Dis"},{"issue":"1","key":"451_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-022-02584-y","volume":"22","author":"L Abid","year":"2022","unstructured":"Abid L, Hammami R, Chamtouri I, et al. Epidemiologic features and management of hypertension in Tunisia, the results from the Hypertension National Registry (NaTuRe HTN). BMC Cardiovasc Disord. 2022;22(1):131. https:\/\/doi.org\/10.1186\/s12872-022-02584-y.","journal-title":"BMC Cardiovasc Disord"},{"issue":"08\u201309","key":"451_CR30","first-page":"767","volume":"99","author":"L Abid","year":"2021","unstructured":"Abid L, Zakhama L, Trabelsi R, et al. Clinical practice guidelines. Management of hypertension in Tunisian adults [in French]. Tunis Med. 2021;99(08\u201309):767\u2013846.","journal-title":"Tunis Med"},{"issue":"3","key":"451_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/14796678.2025.2465218","volume":"21","author":"B Kichou","year":"2025","unstructured":"Kichou B, Bouraghda A, Lahmar HMA, et al. The role of single-pill ACE inhibitor\/CCB combination for hypertension: an Algerian view via the nominal group technique. Future Cardiol. 2025;21(3):155\u201366. https:\/\/doi.org\/10.1080\/14796678.2025.2465218.","journal-title":"Future Cardiol"},{"issue":"3","key":"451_CR32","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1161\/HYPERTENSIONAHA.120.12857","volume":"77","author":"A Persu","year":"2021","unstructured":"Persu A, Lopez-Sublet M, Algharably EAE, Kreutz R. Starting antihypertensive drug treatment with combination therapy: controversies in hypertension\u2014pro side of the argument. Hypertension. 2021;77(3):800\u20135. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.12857.","journal-title":"Hypertension"},{"issue":"3","key":"451_CR33","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1161\/HYPERTENSIONAHA.120.12858","volume":"77","author":"ZY Zhang","year":"2021","unstructured":"Zhang ZY, Yu YL, Asayama K, Hansen TW, Maestre GE, Staessen JA. Starting antihypertensive drug treatment with combination therapy: controversies in hypertension\u2014con side of the argument. Hypertension. 2021;77(3):788\u201398. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.12858.","journal-title":"Hypertension"},{"issue":"9489","key":"451_CR34","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/s0140-6736(05)67185-1","volume":"366","author":"B Dahl\u00f6f","year":"2005","unstructured":"Dahl\u00f6f B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895\u2013906. https:\/\/doi.org\/10.1016\/s0140-6736(05)67185-1.","journal-title":"Lancet"},{"issue":"5","key":"451_CR35","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.ahj.2009.12.042","volume":"159","author":"ME Bertrand","year":"2010","unstructured":"Bertrand ME, Ferrari R, Remme WJ, Simoons ML, Deckers JW, Fox KM. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J. 2010;159(5):795\u2013802. https:\/\/doi.org\/10.1016\/j.ahj.2009.12.042.","journal-title":"Am Heart J"},{"issue":"3","key":"451_CR36","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s40256-018-00314-4","volume":"19","author":"NR Poulter","year":"2019","unstructured":"Poulter NR, Dolan E, Gupta AK, O\u2019Brien E, Whitehouse A, Sever PS. Efficacy and safety of incremental dosing of a new single-pill formulation of perindopril and amlodipine in the management of hypertension. Am J Cardiovasc Drugs. 2019;19(3):313\u201323. https:\/\/doi.org\/10.1007\/s40256-018-00314-4.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"451_CR37","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40256-017-0232-5","volume":"17","author":"CI Liakos","year":"2017","unstructured":"Liakos CI, Papadopoulos DP, Kotsis VT. Adherence to treatment, safety, tolerance, and effectiveness of perindopril\/amlodipine fixed-dose combination in Greek patients with hypertension and stable coronary artery disease: a pan-Hellenic prospective observational study of daily clinical practice. Am J Cardiovasc Drugs. 2017;17(5):391\u20138. https:\/\/doi.org\/10.1007\/s40256-017-0232-5.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"3","key":"451_CR38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/bf03256570","volume":"9","author":"VK Bahl","year":"2009","unstructured":"Bahl VK, Jadhav UM, Thacker HP. Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study. Am J Cardiovasc Drugs. 2009;9(3):135\u201342. https:\/\/doi.org\/10.1007\/bf03256570.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"12","key":"451_CR39","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/hjh.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, et al. 2023 ESH guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874\u20132071. https:\/\/doi.org\/10.1097\/hjh.0000000000003480.","journal-title":"J Hypertens"},{"key":"451_CR40","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0001019444.12431.fc","volume":"42","author":"SS El Khayat","year":"2024","unstructured":"El Khayat SS, Mba CM, Mbanya A, Mbanya JC, Benouna EGM. SYNERGIA-MOROCCO: effectiveness of hypertension management with an amlodipine and perindopril arginine-based strategy in Morocco: study design and preliminary data [ESH abstract]. J Hypertens. 2024;42:e13. https:\/\/doi.org\/10.1097\/01.hjh.0001019444.12431.fc.","journal-title":"J Hypertens"},{"issue":"25","key":"451_CR41","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","volume":"82","author":"GA Mensah","year":"2023","unstructured":"Mensah GA, Fuster V, Murray CJL, Roth GA. Global burden of cardiovascular diseases and risks, 1990\u20132022. J Am Coll Cardiol. 2023;82(25):2350\u2013473. https:\/\/doi.org\/10.1016\/j.jacc.2023.11.007.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"451_CR42","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/14796678.2025.2479970","volume":"21","author":"AJ Manolis","year":"2025","unstructured":"Manolis AJ, Collins P, L\u00f3pez-Send\u00f3n J. Diagnosing and treating stable angina: a contemporary approach for practicing physicians. Future Cardiol. 2025;21(5):291\u2013303. https:\/\/doi.org\/10.1080\/14796678.2025.2479970.","journal-title":"Future Cardiol"},{"issue":"1","key":"451_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-023-03458-7","volume":"23","author":"A Soufiani","year":"2023","unstructured":"Soufiani A, Chraibi H, Asfalou I, et al. The national Moroccan registry of ST-elevation myocardial infarction (MR-MI). BMC Cardiovasc Disord. 2023;23(1):419. https:\/\/doi.org\/10.1186\/s12872-023-03458-7.","journal-title":"BMC Cardiovasc Disord"},{"issue":"11","key":"451_CR44","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","volume":"297","author":"PG Steg","year":"2007","unstructured":"Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197\u2013206. https:\/\/doi.org\/10.1001\/jama.297.11.1197.","journal-title":"JAMA"},{"issue":"6","key":"451_CR45","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1177\/1074248417698224","volume":"22","author":"SK Padala","year":"2017","unstructured":"Padala SK, Lavelle MP, Sidhu MS, et al. Antianginal therapy for stable ischemic heart disease: a contemporary review. J Cardiovasc Pharmacol Ther. 2017;22(6):499\u2013510. https:\/\/doi.org\/10.1177\/1074248417698224.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"8","key":"451_CR46","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00392-013-0568-z","volume":"102","author":"L Jespersen","year":"2013","unstructured":"Jespersen L, Abildstr\u00f8m SZ, Hvelplund A, Prescott E. Persistent angina: highly prevalent and associated with long-term anxiety, depression, low physical functioning, and quality of life in stable angina pectoris. Clin Res Cardiol. 2013;102(8):571\u201381. https:\/\/doi.org\/10.1007\/s00392-013-0568-z.","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"451_CR47","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2459\/jcm.0000000000001707","volume":"26","author":"A Dzudie","year":"2025","unstructured":"Dzudie A, Aatif B, Appiah LT, et al. Chronic coronary syndrome in Africa: current management and service challenges, and opportunities for optimizing patient care. J Cardiovasc Med (Hagerstown). 2025;26(4):172\u201381. https:\/\/doi.org\/10.2459\/jcm.0000000000001707.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"36","key":"451_CR48","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415\u2013537. https:\/\/doi.org\/10.1093\/eurheartj\/ehae177.","journal-title":"Eur Heart J"},{"issue":"2","key":"451_CR49","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/nrcardio.2017.131","volume":"15","author":"R Ferrari","year":"2018","unstructured":"Ferrari R, Camici PG, Crea F, et al. A \u2018diamond\u2019 approach to personalized treatment of angina. Nat Rev Cardiol. 2018;15(2):120\u201332. https:\/\/doi.org\/10.1038\/nrcardio.2017.131.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"451_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-024-03501-5","volume":"25","author":"J Labidi","year":"2024","unstructured":"Labidi J, Harzallah A, Kaab BB, et al. Prevalence of chronic kidney disease in Tunisian diabetics: the TUN-CKDD survey. BMC Nephrol. 2024;25(1):67. https:\/\/doi.org\/10.1186\/s12882-024-03501-5.","journal-title":"BMC Nephrol"},{"issue":"6","key":"451_CR51","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/dme.12685","volume":"32","author":"SM Babineaux","year":"2015","unstructured":"Babineaux SM, Toaima D, Boye KS, et al. Multi-country retrospective observational study of the management and outcomes of patients with type\u00a02 diabetes during Ramadan in 2010 (CREED). Diabet Med. 2015;32(6):819\u201328. https:\/\/doi.org\/10.1111\/dme.12685.","journal-title":"Diabet Med"},{"key":"451_CR52","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.diabres.2019.02.020","volume":"151","author":"M Hassanein","year":"2019","unstructured":"Hassanein M, Al Awadi FF, El Hadidy KES, et al. The characteristics and pattern of care for the type\u00a02 diabetes mellitus population in the MENA region during Ramadan: an international prospective study (DAR-MENA T2DM). Diabetes Res Clin Pract. 2019;151:275\u201384. https:\/\/doi.org\/10.1016\/j.diabres.2019.02.020.","journal-title":"Diabetes Res Clin Pract"},{"key":"451_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109185","volume":"185","author":"M Hassanein","year":"2022","unstructured":"Hassanein M, Afandi B, Yakoob Ahmedani M, et al. Diabetes and Ramadan: practical guidelines 2021. Diabetes Res Clin Pract. 2022;185:109185. https:\/\/doi.org\/10.1016\/j.diabres.2021.109185.","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"451_CR54","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.2337\/dc10-0896","volume":"33","author":"M Al-Arouj","year":"2010","unstructured":"Al-Arouj M, Assaad-Khalil S, Buse J, et al. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care. 2010;33(8):1895\u2013902. https:\/\/doi.org\/10.2337\/dc10-0896.","journal-title":"Diabetes Care"},{"key":"451_CR55","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4103\/ijmbs.ijmbs_49_20","volume":"12","author":"B Afandi","year":"2020","unstructured":"Afandi B, Beshyah S, Hassanein M, Jabbar A, Khalil A. The individualization of care for people with diabetes during Ramadan fasting: a narrative review. Ibnosina J Med Biomed Sci. 2020;12:98\u2013107. https:\/\/doi.org\/10.4103\/ijmbs.ijmbs_49_20.","journal-title":"Ibnosina J Med Biomed Sci"},{"issue":"01","key":"451_CR56","doi-asserted-by":"publisher","first-page":"020","DOI":"10.1055\/s-0045-1813010","volume":"09","author":"B Afandi","year":"2026","unstructured":"Afandi B, Suliman M, Shaikh S, Beshyah S, Hasannien M. The 2026 update of the IDF-DAR risk calculator for fasting in people with diabetes. J Diabetes Endocr Pract. 2026;09(01):020\u20138. https:\/\/doi.org\/10.1055\/s-0045-1813010.","journal-title":"J Diabetes Endocr Pract"},{"issue":"1","key":"451_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.31038\/EDMJ.2025912","volume":"9","author":"R Malek","year":"2025","unstructured":"Malek R, Nechadi A, Sefsaf M, Mehtal A, Mallem N. Changes in metabolic markers during Ramadan fasting according to the IDF-DAR risk score 2021 in patients with type\u00a01 and type\u00a02 diabetes: a multicentre study in Algeria. Endocrinol Diabetes Metab J. 2025;9(1):1\u20137. https:\/\/doi.org\/10.31038\/EDMJ.2025912.","journal-title":"Endocrinol Diabetes Metab J"},{"key":"451_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101860","volume":"57","author":"SR Chowdhury","year":"2023","unstructured":"Chowdhury SR, Chandra Das D, Sunna TC, Beyene J, Hossain A. Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta-analysis. EClinicalMedicine. 2023;57:101860. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101860.","journal-title":"EClinicalMedicine"},{"issue":"8","key":"451_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19084726","volume":"19","author":"X Cheng","year":"2022","unstructured":"Cheng X, Ma T, Ouyang F, Zhang G, Bai Y. Trends in the prevalence of cardiometabolic multimorbidity in the United States, 1999-2018. Int J Environ Res Public Health. 2022;19(8):4726. https:\/\/doi.org\/10.3390\/ijerph19084726.","journal-title":"Int J Environ Res Public Health"},{"key":"451_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhip.2021.100193","volume":"2","author":"R Sewpaul","year":"2021","unstructured":"Sewpaul R, Mbewu AD, Fagbamigbe AF, Kandala NB, Reddy SP. Prevalence of multimorbidity of cardiometabolic conditions and associated risk factors in a population-based sample of South Africans: a cross-sectional study. Public Health Pract (Oxf). 2021;2:100193. https:\/\/doi.org\/10.1016\/j.puhip.2021.100193.","journal-title":"Public Health Pract (Oxf)"},{"issue":"3","key":"451_CR61","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024476","volume":"9","author":"D Zhang","year":"2019","unstructured":"Zhang D, Tang X, Shen P, et al. Multimorbidity of cardiometabolic diseases: prevalence and risk for mortality from one million Chinese adults in a longitudinal cohort study. BMJ Open. 2019;9(3):e024476. https:\/\/doi.org\/10.1136\/bmjopen-2018-024476.","journal-title":"BMJ Open"},{"issue":"20","key":"451_CR62","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/cir.0000000000001186","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: a scientific statement from the American Heart Association. Circulation. 2023;148(20):1636\u201364. https:\/\/doi.org\/10.1161\/cir.0000000000001186.","journal-title":"Circulation"},{"issue":"5","key":"451_CR63","first-page":"587","volume":"3","author":"L Erhardt","year":"2007","unstructured":"Erhardt L, Moller R, Puig JG. Comprehensive cardiovascular risk management\u2014what does it mean in practice? Vasc Health Risk Manag. 2007;3(5):587\u2013603.","journal-title":"Vasc Health Risk Manag"},{"issue":"9457","key":"451_CR64","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/s0140-6736(05)17833-7","volume":"365","author":"R Jackson","year":"2005","unstructured":"Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual\u2019s absolute cardiovascular risk. Lancet. 2005;365(9457):434\u201341. https:\/\/doi.org\/10.1016\/s0140-6736(05)17833-7.","journal-title":"Lancet"},{"issue":"1 Pt 2","key":"451_CR65","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0002-8703(91)90861-b","volume":"121","author":"KM Anderson","year":"1991","unstructured":"Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121(1 Pt 2):293\u20138. https:\/\/doi.org\/10.1016\/0002-8703(91)90861-b.","journal-title":"Am Heart J"},{"issue":"2","key":"451_CR66","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1161\/hypertensionaha.119.14240","volume":"75","author":"FD Fuchs","year":"2020","unstructured":"Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75(2):285\u201392. https:\/\/doi.org\/10.1161\/hypertensionaha.119.14240.","journal-title":"Hypertension"},{"issue":"5","key":"451_CR67","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","volume":"174","author":"J Cheng","year":"2014","unstructured":"Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014;174(5):773\u201385. https:\/\/doi.org\/10.1001\/jamainternmed.2014.348.","journal-title":"JAMA Intern Med"},{"issue":"15","key":"451_CR68","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000010256","volume":"97","author":"X Lv","year":"2018","unstructured":"Lv X, Zhang Y, Niu Y, Song Q, Zhao Q. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type\u00a02 diabetes mellitus: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2018;97(15):e0256. https:\/\/doi.org\/10.1097\/md.0000000000010256.","journal-title":"Medicine (Baltimore)"},{"key":"451_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2021.100725","volume":"33","author":"JL Benham","year":"2021","unstructured":"Benham JL, Booth JE, Sigal RJ, Daskalopoulou SS, Leung AA, Rabi DM. Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. Int J Cardiol Heart Vasc. 2021;33:100725. https:\/\/doi.org\/10.1016\/j.ijcha.2021.100725.","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"1","key":"451_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/obr.12753","volume":"20","author":"Y Jia","year":"2019","unstructured":"Jia Y, Lao Y, Zhu H, Li N, Leung SW. Is metformin still the most efficacious first-line oral hypoglycaemic drug in treating type\u00a02 diabetes? A network meta-analysis of randomized controlled trials. Obes Rev. 2019;20(1):1\u201312. https:\/\/doi.org\/10.1111\/obr.12753.","journal-title":"Obes Rev"},{"key":"451_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-018-0331-8","volume":"10","author":"LA Leiter","year":"2018","unstructured":"Leiter LA, Shestakova MV, Satman I. Effectiveness of gliclazide MR 60\u00a0mg in the management of type\u00a02 diabetes: analyses from the EASYDia trial. Diabetol Metab Syndr. 2018;10:30. https:\/\/doi.org\/10.1186\/s13098-018-0331-8.","journal-title":"Diabetol Metab Syndr"},{"issue":"24","key":"451_CR72","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type\u00a02 diabetes. N Engl J Med. 2008;358(24):2560\u201372. https:\/\/doi.org\/10.1056\/NEJMoa0802987.","journal-title":"N Engl J Med"},{"issue":"8","key":"451_CR73","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1365-2362.2004.01381.x","volume":"34","author":"G Schernthaner","year":"2004","unstructured":"Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type\u00a02 diabetic patients. Eur J Clin Invest. 2004;34(8):535\u201342. https:\/\/doi.org\/10.1111\/j.1365-2362.2004.01381.x.","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"451_CR74","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type\u00a02 diabetes. N Engl J Med. 2018;379(7):633\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1800256.","journal-title":"N Engl J Med"},{"key":"451_CR75","doi-asserted-by":"publisher","unstructured":"Global Cardiovascular Risk Consortium, Magnussen C, Alegre-Diaz J, et al. Global effect of cardiovascular risk factors on lifetime estimates. N Engl J Med. 2025;393(2):125\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2415879.","DOI":"10.1056\/NEJMoa2415879"},{"issue":"21","key":"451_CR76","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.030240","volume":"12","author":"SL Jackson","year":"2023","unstructured":"Jackson SL, Woodruff RC, Nagavedu K, et al. Association between hypertension and diabetes control and COVID-19 severity: National Patient-Centered Clinical Research Network, United States, March 2020 to February 2022. J Am Heart Assoc. 2023;12(21):e030240. https:\/\/doi.org\/10.1161\/JAHA.122.030240.","journal-title":"J Am Heart Assoc"},{"key":"451_CR77","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2147\/ppa.S296280","volume":"15","author":"O Ogungbe","year":"2021","unstructured":"Ogungbe O, Byiringiro S, Adedokun-Afolayan A, et al. Medication adherence interventions for cardiovascular disease in low- and middle-income countries: a systematic review. Patient Prefer Adher. 2021;15:885\u201397. https:\/\/doi.org\/10.2147\/ppa.S296280.","journal-title":"Patient Prefer Adher"},{"issue":"1","key":"451_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-21916-8","volume":"12","author":"X Yan","year":"2022","unstructured":"Yan X, Mudiganti S, Husby H, Hudnut A, Gbotoe M, Jones JB. Medication non-adherence and therapeutic inertia independently contribute to poor disease control for cardiometabolic diseases. Sci Rep. 2022;12(1):18936. https:\/\/doi.org\/10.1038\/s41598-022-21916-8.","journal-title":"Sci Rep"},{"key":"451_CR79","unstructured":"World Health Organization. Adherence to long-term therapies: evidence for action. 2003. https:\/\/iris.who.int\/handle\/10665\/42682. Accessed 13 Nov 2025."},{"issue":"8","key":"451_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101233","volume":"48","author":"AA Khan","year":"2023","unstructured":"Khan AA, Siddiqui SA, Yasmin F, et al. The era of polypills in the management of cardiovascular diseases: are we there yet? Curr Probl Cardiol. 2023;48(8):101233. https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101233.","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"451_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12010044","volume":"12","author":"E Menditto","year":"2020","unstructured":"Menditto E, Orlando V, De Rosa G, et al. Patient centric pharmaceutical drug product design-the impact on medication adherence. Pharmaceutics. 2020;12(1):44. https:\/\/doi.org\/10.3390\/pharmaceutics12010044.","journal-title":"Pharmaceutics"},{"issue":"5","key":"451_CR82","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-017-0853-y","volume":"19","author":"A Roy","year":"2017","unstructured":"Roy A, Naik N, Srinath Reddy K. Strengths and limitations of using the polypill in cardiovascular prevention. Curr Cardiol Rep. 2017;19(5):45. https:\/\/doi.org\/10.1007\/s11886-017-0853-y.","journal-title":"Curr Cardiol Rep"},{"issue":"2","key":"451_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12020190","volume":"12","author":"A Baumgartner","year":"2020","unstructured":"Baumgartner A, Drame K, Geutjens S, Airaksinen M. Does the polypill improve patient adherence compared to its individual formulations? A systematic review. Pharmaceutics. 2020;12(2):190. https:\/\/doi.org\/10.3390\/pharmaceutics12020190.","journal-title":"Pharmaceutics"},{"issue":"2","key":"451_CR84","doi-asserted-by":"publisher","first-page":"97","DOI":"10.7326\/0003-4819-155-2-201107190-00005","volume":"155","author":"ND Berkman","year":"2011","unstructured":"Berkman ND, Sheridan SL, Donahue KE, Halpern DJ, Crotty K. Low health literacy and health outcomes: an updated systematic review. Ann Intern Med. 2011;155(2):97\u2013107. https:\/\/doi.org\/10.7326\/0003-4819-155-2-201107190-00005.","journal-title":"Ann Intern Med"},{"key":"451_CR85","unstructured":"Process Communication Model. PCM. 2025. https:\/\/processcommunicationmodel.com\/. Accessed 12 Nov 2025."},{"key":"451_CR86","unstructured":"Kahler T. The process therapy model: the sixth personality types with adaptations. Little Rock: Taibi Kahler Associates; 2008."},{"issue":"4","key":"451_CR87","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/ans.16351","volume":"91","author":"MI Andrew","year":"2021","unstructured":"Andrew MI, Wilkinson S, Wylie N, Salter A. Evaluation of Process Communication Model training for surgeons and other healthcare professionals: a survey. ANZ J Surg. 2021;91(4):487\u20138. https:\/\/doi.org\/10.1111\/ans.16351.","journal-title":"ANZ J Surg"},{"key":"451_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106462","volume":"115","author":"M Sultan","year":"2021","unstructured":"Sultan M, Brown EM, Thomas RH. Clinicians embracing social media: potential and pitfalls. Epilepsy Behav. 2021;115:106462. https:\/\/doi.org\/10.1016\/j.yebeh.2019.106462.","journal-title":"Epilepsy Behav"},{"issue":"3","key":"451_CR89","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1007\/s12325-024-03103-5","volume":"42","author":"W Almahmeed","year":"2025","unstructured":"Almahmeed W, Alabadla Z, Al Awadi F, et al. Improving therapeutic adherence and reducing therapeutic inertia in the management of people with cardiometabolic diseases: a call-to-action from the Middle East. Adv Ther. 2025;42(3):1340\u201359. https:\/\/doi.org\/10.1007\/s12325-024-03103-5.","journal-title":"Adv Ther"},{"issue":"1","key":"451_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-020-00559-7","volume":"12","author":"F Andreozzi","year":"2020","unstructured":"Andreozzi F, Candido R, Corrao S, et al. Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review. Diabetol Metab Syndr. 2020;12(1):52. https:\/\/doi.org\/10.1186\/s13098-020-00559-7.","journal-title":"Diabetol Metab Syndr"},{"key":"451_CR91","first-page":"12","volume":"492","author":"F Liot\u00e9","year":"2023","unstructured":"Liot\u00e9 F. Clinical or therapeutic inertia: a plague of chronic diseases, including rheumatic diseases [in French]. La Lett Rhumatol. 2023;492:12\u20137.","journal-title":"La Lett Rhumatol"},{"key":"451_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-015-0260-x","volume":"14","author":"SK Paul","year":"2015","unstructured":"Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type\u00a02 diabetes. Cardiovasc Diabetol. 2015;14:100. https:\/\/doi.org\/10.1186\/s12933-015-0260-x.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"451_CR93","doi-asserted-by":"publisher","DOI":"10.2196\/10775","volume":"20","author":"I Contreras","year":"2018","unstructured":"Contreras I, Vehi J. Artificial intelligence for diabetes management and decision support: literature review. J Med Internet Res. 2018;20(5):e10775. https:\/\/doi.org\/10.2196\/10775.","journal-title":"J Med Internet Res"},{"issue":"16","key":"451_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e36112","volume":"10","author":"PN Srinivasu","year":"2024","unstructured":"Srinivasu PN, Ahmed S, Hassaballah M, Almusallam N. An explainable artificial intelligence software system for predicting diabetes. Heliyon. 2024;10(16):e36112. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36112.","journal-title":"Heliyon"},{"issue":"10","key":"451_CR95","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/s41591-020-1010-5","volume":"26","author":"R Avram","year":"2020","unstructured":"Avram R, Olgin JE, Kuhar P, et al. A digital biomarker of diabetes from smartphone-based vascular signals. Nat Med. 2020;26(10):1576\u201382. https:\/\/doi.org\/10.1038\/s41591-020-1010-5.","journal-title":"Nat Med"},{"key":"451_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2021.103693","volume":"115","author":"J Li","year":"2021","unstructured":"Li J, Yuan P, Hu X, et al. A tongue features fusion approach to predicting prediabetes and diabetes with machine learning. J Biomed Inform. 2021;115:103693. https:\/\/doi.org\/10.1016\/j.jbi.2021.103693.","journal-title":"J Biomed Inform"},{"issue":"1","key":"451_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41378-022-00355-5","volume":"8","author":"T Chang","year":"2022","unstructured":"Chang T, Li H, Zhang N, et al. Highly integrated watch for noninvasive continual glucose monitoring. Microsyst Nanoeng. 2022;8(1):25. https:\/\/doi.org\/10.1038\/s41378-022-00355-5.","journal-title":"Microsyst Nanoeng"},{"issue":"2","key":"451_CR98","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/19322968221116393","volume":"18","author":"D Dave","year":"2024","unstructured":"Dave D, Vyas K, Branan K, et al. Detection of hypoglycemia and hyperglycemia using noninvasive wearable sensors: electrocardiograms and accelerometry. J Diabetes Sci Technol. 2024;18(2):351\u201362. https:\/\/doi.org\/10.1177\/19322968221116393.","journal-title":"J Diabetes Sci Technol"},{"issue":"1","key":"451_CR99","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12553-022-00719-x","volume":"13","author":"M Andellini","year":"2023","unstructured":"Andellini M, Haleem S, Angelini M, et al. Artificial intelligence for non-invasive glycaemic-events detection via ECG in a paediatric population: study protocol. Health Technol. 2023;13(1):145\u201354. https:\/\/doi.org\/10.1007\/s12553-022-00719-x.","journal-title":"Health Technol"},{"issue":"10176","key":"451_CR100","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S0140-6736(19)30368-X","volume":"393","author":"RM Bergenstal","year":"2019","unstructured":"Bergenstal RM, Johnson M, Passi R, et al. Automated insulin dosing guidance to optimise insulin management in patients with type\u00a02 diabetes: a multicentre, randomised controlled trial. Lancet. 2019;393(10176):1138\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(19)30368-X.","journal-title":"Lancet"},{"issue":"6","key":"451_CR101","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41551-021-00745-6","volume":"5","author":"K Zhang","year":"2021","unstructured":"Zhang K, Liu X, Xu J, et al. Deep-learning models for the detection and incidence prediction of chronic kidney disease and type\u00a02 diabetes from retinal fundus images. Nat Biomed Eng. 2021;5(6):533\u201345. https:\/\/doi.org\/10.1038\/s41551-021-00745-6.","journal-title":"Nat Biomed Eng"},{"key":"451_CR102","unstructured":"H\u00f4pitaux Universitaires Gen\u00e8ve. \u201cconfIAnce\u201d, the general medical information chatbot, a Swiss first [in French]. 2025. https:\/\/www.hug.ch\/medias\/communique-presse\/confiance-chatbot-dinformation-medicale-generale-premiere-suisse. Accessed 13 Nov 2025."},{"issue":"1","key":"451_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-024-04390-0","volume":"24","author":"H Soleimani","year":"2024","unstructured":"Soleimani H, Nasrollahizadeh A, Nasrollahizadeh A, et al. Cardiovascular disease burden in the North Africa and Middle East region: an analysis of the global burden of disease study 1990\u20132021. BMC Cardiovasc Disord. 2024;24(1):712. https:\/\/doi.org\/10.1186\/s12872-024-04390-0.","journal-title":"BMC Cardiovasc Disord"},{"issue":"5","key":"451_CR104","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cjca.2017.12.005","volume":"34","author":"JR Petrie","year":"2018","unstructured":"Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34(5):575\u201384. https:\/\/doi.org\/10.1016\/j.cjca.2017.12.005.","journal-title":"Can J Cardiol"},{"issue":"Suppl_1","key":"451_CR105","doi-asserted-by":"publisher","DOI":"10.1161\/circ.149.suppl_1.P263","volume":"149","author":"A Burch","year":"2024","unstructured":"Burch A, Lee E, Shackelford P, Bolin P. Cardiometabolic multimorbidity among rural low-wage workers participating in a worksite-based health assessment. Circulation. 2024;149(Suppl_1):P263. https:\/\/doi.org\/10.1161\/circ.149.suppl_1.P263.","journal-title":"Circulation"},{"key":"451_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fcdhc.2025.1495849","volume":"6","author":"M Belhadj","year":"2025","unstructured":"Belhadj M, Malek R, Baghous H, et al. Perspectives of type\u00a02 diabetes mellitus management in Algeria: a comprehensive expert review. Front Clin Diabetes Healthc. 2025;6:1495849. https:\/\/doi.org\/10.3389\/fcdhc.2025.1495849.","journal-title":"Front Clin Diabetes Healthc"},{"key":"451_CR107","unstructured":"World Health Organization. Algeria: health data overview for the People\u2019s Democratic Republic of Algeria. 2025. https:\/\/data.who.int\/countries\/012. Accessed 13 Nov 2025."}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00451-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00451-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00451-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:41:24Z","timestamp":1780072884000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-026-00451-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":107,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["451"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00451-x","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Faouzi Addad, Walid Amara, Ahmed Bennis, Franck Boccara, M. Abed Bouraghda, Mohammed Chettibi, Hinde Iraqi, Selma Siham El Khayat, In\u00e8s Khochtali, Nadia Laredj, Rachid Malek, Habib Skhiri, Aida Soufiani and Marilucy Lopez-Sublet have received research fees, speaker fees or honoraria from Servier. Hinde Iraqi has additionally received speaker fees or honoraria from Servier, AstraZeneca, Viatris, Novo Nordisk, Sanofi and Sothema; and consultancy fees from CooperPharma and the World Health Organization. Each author participates in expert assessments or continuing education or receives research funding, speaker fees or honoraria from other industry partners. Further information regarding the author disclosures is available on\n                      \n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}